galapagosgilead

2020年10月16日 — Gilead can exercise its $250 million option upon the completion of the phase 2 ROCCELLA trial. With top-line data from the study now available, ...

Galapagos and Gilead are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” For purposes of this Agreement, the ...

2021年2月10日 — A $5 billion deal to develop a drug called zirataxestat, for idiopathic pulmonary fibrosis, goes up in flames.

2019年7月14日 — Gilead will have access to Galapagos' established research base, which includes more than 500 scientists, and to Galapagos' unique platform, ...

2023年8月4日 — Once a biotech powerhouse so attractive that it drew a $5 billion partnership with Gilead in 2019, Galapagos has seen its value plummet. After ...

2020年12月15日 — Gilead and Galapagos will continue to investigate the potential for filgotinib to support patients living with Inflammatory Bowel Disease (IBD).

2021年3月4日 — In December, Gilead deemed the treatment unlikely to gain FDA approval for rheumatoid arthritis without “substantial additional clinical studies ...

2021年2月10日 — Gilead has now said it would give up on a U.S. approval for filgotinib in rheumatoid arthritis, pay Galapagos €160 million to take over most ...

2019年7月14日 — Gilead will maintain option rights to Galapagos' programs through the 10-year term of the collaboration and for up to an additional three years ...

Galapagos will receive tiered royalties ranging from 20 – 24% on net sales of all our products licensed by Gilead in countries outside Europe as part of the ...